🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. Placebo for TransCon CNP, TransCon CNP 3.9 mg CNP-38/vial, Navepegritide 2.8 mg CNP(89-126), Navepegritide 1.3 mg CNP(89-126)

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  2. Placebo for bms-986435-01

    Bristol-Myers Squibb Australia Pty Ltd

    Heart failure with preserved ejection fraction (HFpEF)

    phase 2 small molecule active

    1 trial

  3. Placebo for petrelintide, Petrelintide, Petrelintide

    Zealand Pharma A/S

    Weight management

    phase 2 small molecule active

    1 trial

  4. Placebo for pf-07328948 tablet (CCI) mg, Placebo for pf-07328948 tablet (CCI) mg

    Pfizer Australia Pty Ltd

    Heart failure

    phase 2 small molecule active

    1 trial

  5. Placebo for ponsegromab (PF-06946860) solution for injection, Ponsegromab (PF-06946860)

    Pfizer Australia Pty Ltd

    Cancer cachexia

    phase 2 small molecule active

    1 trial

  6. Placebo is identical with the test product and just does not contain active substance.

    Lacuna Pharma Pty Ltd

    Prurigo Nodularis

    phase 2 small molecule active

    1 trial

  7. Placebo matching BI 764198, BI 764198

    Boehringer Ingelheim

    Proteinuric kidney diseases

    phase 2 small molecule active

    1 trial

  8. Placebo matching BLU-808, tablet, BLU-808, BLU-808

    Blueprint Medicines (Netherlands) B.V.

    Chronic Inducible Urticaria and Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  9. Placebo matching REGN9933, REGN7508, REGN9933, Placebo matching REGN7508

    Lacuna Pharma Pty Ltd

    Venous Thromboembolism

    phase 2 small molecule active

    1 trial

  10. Placebo matching with ZED1227 capsules of Dr. Falk Pharma GmbH, CEC02, CEC03

    Dr. Falk Pharma GmbH

    Celiac Disease

    phase 2 small molecule active

    1 trial

  11. Placebo of Dexamfetamine sulfate 20 mg modified-release capsule, Dexamfetamine sulfate 20 mg modified-release capsule, Attentin 5 mg, Tablette, Dexamfetamine sulfate 15 mg modified-release capsule, Dexamfetamine sulfate 10 mg modified-release capsule, Placebo of Attentin 5 mg 10 mg tablets, Placebo of Dexamfetamine sulfate 15 mg modified-release capsule, Attentin 10 mg Tablette, Placebo of Dexamfetamine sulfate 10 mg modified-release capsule

    Lacuna Pharma Pty Ltd

    Adults with ADHD and moderate to severe depression

    phase 2 small molecule active

    1 trial

  12. Placebo of IPN10200, IPN10200

    Ipsen

    Cervical Dystonia

    phase 2 small molecule active

    1 trial

  13. Placebo of NAL, NACYSTELYN

    Laboratoire HRA Pharma

    Obstructive Sleep Apnea

    phase 2 small molecule active

    1 trial

  14. Placebo of leflunomide, Arava 20 mg film-coated tablets, Mycophenolate mofetil Teva 500 mg film-coated tablets, Placebo of mycophenolate mofetil, Placebo of hydroxychloroquine, PLAQUENIL 200 mg, comprimé pelliculé

    Pari Pharma GmbH

    Primary Sjogren's syndrome

    phase 2 small molecule active

    1 trial

  15. Placebo oral capsule

    United Therapeutics Europe Ltd

    Osteoarthritis, Knee

    phase 2 small molecule completed

    1 trial

  16. Placebo session 1, Aprepitant session 2

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  17. Placebo solution for injection matching COR-1167, COR-1167

    Lacuna Pharma Pty Ltd

    Worsening Heart Failure

    phase 2 small molecule active

    1 trial

  18. Placebo sterile solution for SC injection, Obexelimab

    Zenas BioPharma

    RELAPSING MULTIPLE SCLEROSIS

    phase 2 small molecule active

    1 trial

  19. Placebo tablets are produced with the same appearance as the Valganciclovir tablets, with the same content except for the active compound., VALGANCICLOVIR

    The George Institute

    Glioblstoma WHO grade IV

    phase 2 small molecule active

    1 trial

  20. Placebo to ARGX-117 IV concentrate solution for infusion, ARGX-117

    argenx

    Myositis, Dermatomyositis

    phase 2 small molecule active

    1 trial

  21. Placebo to ARGX-117 IV, ARGX-117, ARGX-117

    argenx

    Multifocal Motor Neuropathy

    phase 2 small molecule active

    1 trial

  22. Placebo to ARGX-119 concentrate for solution for infusion, ARGX-119

    argenx

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  23. Placebo to AVTX-009, AVTX-009

    Avalo Therapeutics

    Hidradenitis suppurativa (HS)

    phase 2 small molecule active

    1 trial

  24. Placebo to BAY 3401016, BAY 3401016

    Bayer AG

    Alport Syndrome, Chronic kidney disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources